Australia markets closed

Exopharm Limited (EX1.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0120-0.0020 (-14.29%)
At close: 01:48PM AEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2022
30/06/2021
30/06/2020
30/06/2019
Total revenue
-
99.73
-
2,615
-
Gross profit
-
99.73
-
2,615
-
Operating expenses
Research development
2,318
2,535
3,166
2,619
496.688
Selling general and administrative
8,755
9,679
8,230
4,792
1,364
Total operating expenses
13,084
14,212
12,667
8,005
2,372
Operating income or loss
-12,621
-14,113
-12,667
-8,005
-2,372
Interest expense
-
81.225
-
-
-
Total other income/expenses net
5,939
4,107
4,192
2,665
-
Income before tax
-6,930
-10,084
-8,468
-5,279
-2,283
Income tax expense
0
0
0
0
0
Income from continuing operations
-6,930
-10,084
-8,468
-5,279
-2,283
Net income
-6,930
-10,084
-8,468
-5,279
-2,283
Net income available to common shareholders
-6,930
-10,084
-8,468
-5,279
-2,283
Basic EPS
-
-0.06
-0.06
-0.06
-0.04
Diluted EPS
-
-0.06
-0.06
-0.06
-0.04
Basic average shares
-
157,192
130,599
94,005
56,711
Diluted average shares
-
157,192
130,599
94,005
56,711
EBITDA
-
-8,274
-11,660
-7,622
-2,312